ArticleScientific reports2026
Complete genome sequence and functional characterization of Bacillus amyloliquefaciens NJF-55: a sheep-derived probiotic candidate.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probiogenomics as a Computational Biotechnology Framework: Safety-Gated Genome Analytics for Candidate Probiotic Prioritization and Validation.Computational and structural biotechnology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacillus amyloliquefaciens strain NJF-55, which was isolated from the distal colon of a healthy ram, was investigated as a probiotic candidate. We produced a high-quality assembly comprising a single circular chromosome (3,854,703 bp; 46.1% GC) and a small plasmid (6033 bp), and reconciled multi pipeline annotations to derive a consensus feature set. Functional profiling mapped 2334 genes to 2027 KEGG orthologs (1835 unique), indicating complete central metabolism, broad transport capacity, and stress-adaptation pathways; 94 CAZymes supported glycan turnover and cell-envelope remodeling. Secondary-metabolite mining revealed hallmark Bacillus BGCs—surfactin, fengycin, bacillaene, and macrolactin—and flagged putative novel compounds (a PKS-like region with ~ 7% similarity to the butirosin A/B reference); Five bacteriocin/RiPP regions were identified (class IV lanthipeptide, amylocyclicin, ComX2 pheromone, UviB-like and colicin-like). Genome-safety screening detected no classical virulence determinants or acquired clinically relevant AMR genes; four intact prophages lacked toxin/AMR cargo, and the plasmid encoded no risk loci. Comparative genomics with four reference bacilli yielded a 5,398-cluster pangenome; NJF-55 retained 325 probiotic-associated clusters (largely core) and showed 30 copy-number expansions, notably in the NRPS/PKS and DNA replication/repair families, consistent with a “core-driven, dosage-tuned” architecture. These features suggest that NJF-55 may represent a safe and robust candidate for ruminant gut applications, while underscoring the need for targeted metabolomics and controlled in vivo validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.